Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.
https://www.news-medical.net/n....ews/20240520/Dupilum